We performed a retrospective chart review of patients to determine if the Verigene Gram-negative blood culture (BC-GN) results would lead to earlier deescalation of empiric therapy for inpatients with GN bacteremia with Citrobacter spp., Enterobacter spp., Klebsiella spp., and Escherichia coli to appropriate targeted coverage. A total of 899 records were reviewed from April 2014 to February 2016 from three institutions within the Baylor Scott & White Health network. The cases were reviewed for initial antibiotic coverage, timing of Verigene results, change in antibiotic coverage, and how these changes related to the timing of Verigene results. The lab reported the BC-GN results and final conventional susceptibility results within 2.5 ± 1.3 and 73.6 ± 40.0 hours from the Gram stain, respectively. Overall, 29.1% of patients were transitioned from empiric to targeted therapy at 12.2 ± 13.5 hours in response to BC-GN results, which was significantly earlier (P < 0.001) than results by conventional methods. After accounting for patients already on targeted therapy, polymicrobial infections, and patients deceased or lost to follow-up, we identified antibiotic stewardship opportunities in ∼28% of GN infections. Further subanalysis demonstrated site-specific differences in the uptake of stewardship recommendations, whereby 32.4%, 50.5%, and 15.0% of cases at different hospitals demonstrated the expected change in antibiotics. These results suggest that Verigene had the expected impact in a third of the cases and the results reporting algorithm minimized the real-time involvement of the pharmacist while maintaining optimal patient management. However, this impact varied substantially by clinical site and was tempered by variable initial antibiotic coverage and clinician response.
result comments. Th e goal was to improve patient outcomes by guiding transition of the empiric treatment (vancomycin and piperacillin/tazobactam) to targeted therapy, while simultaneously preventing antibiotic overuse and the development of antibiotic resistance. Th is study aimed to determine if decreasing the time to blood culture result using the BC-GN system paired with well-defi ned ASP-recommended therapy changes would impact clinical outcomes. Th e primary objective was to evaluate the clinical uptake and utilization of the BC-GN results by measuring the reduction in time from positive blood culture to the deescalation of empiric therapy and the switch to the fi rst dose of appropriate antibiotics per the resulting algorithm. As previously published, an algorithm designed using electronic communications and minimum pharmacist intervention was used (7, 8) . We also determined if there were any site-specifi c diff erences in the uptake of stewardship recommendations within the network.
METHODS
Th is was a multisite, retrospective chart review of patients admitted with Gram-negative (GN) bacteremia to Baylor University Medical Center, a 1079-bed tertiary referral center in Dallas, Texas, and two smaller acute care hospitals also within the Baylor Scott and White Health network, 574-bed Baylor All Saints and 296-bed Baylor Irving. Blood cultures were performed at the affi liated reference laboratory, med fusion, in Lewisville, Texas. Molecular testing on the positive blood cultures was performed using Verigene BC-GN panel ( Nanosphere, Inc., Northbrook, IL). Th is study was approved by the institutional review board.
Medical records were reviewed from April 2014 to February 2016 from three sites for initial antibiotic coverage, timing of the appearance of Verigene results in the electronic health record (EHR), change in antibiotic therapy (if any), and how these changes compared to the timing of Verigene results. Times were Clinical uptake of antimicrobial stewardship recommendations following Nanosphere Verigene Blood Culture Gram-negative reporting conventional phenotypic methods, MALDI-TOF and the VITEK®2 (bioMérieux, Durham, NC). Th e fi rst bottle per bacteremic episode that showed a GN organism on Gram stain was tested using the BC-GN. Th e BC-GN was also run if the Gram stain showed mixed organisms with Gram-positive or other Gram stain morphologies.
Th e BC-GN results were called as a critical value to the fl oor and were released in the EHR. For Citrobacter spp. and Enterobacter spp., the Verigene report was accompanied by an interpretive comment suggesting the appropriate antimicrobials were fourth-generation cephalosporins and recommending discontinuation of empiric coverage. For Klebsiella spp. and E. coli, appropriate antimicrobials included third-generation cephalosporins and discontinuation of empiric coverage. Th e stewardship recommendations were developed by a collaborative team of ASP, infectious disease physicians, and laboratory staff .
Student's t test was used to determine statistical signifi cance in cases where intervention was made in response to the rapid Verigene result vs. the availability of the fi nal report based on conventional methods.
RESULTS
Th e patient demographic and laboratory data are summarized in Table 2 . Overall, there was a slight predominance of women (61.2%) in the study cohort. Th e mean age of women was 56.6 ± 19.4 years, signifi cantly lower (P < 0.001) than the mean age of the men (63.6 ± 15.9 years) at the time of the septic episode. Th is was unlikely to have any clinical signifi cance. From the time of the blood collection, the Gram stain was reported within an average of 20.0 ± 10.4 hours and the BC-GN result was reported within 2.5 ± 1.3 hours of the Gram stain. Th e time between Gram stain and fi nal identifi cation and susceptibilities using conventional methods was 73.6 ± 40.0 hours.
Th e distribution of the GN bacterial targets across the three sites evaluated within the Baylor network is shown in Table 3 . Across the three sites evaluated, E. coli was the predominant isolate (72.5%), 14.4% of which harbored extended spectrum beta-lactamases (ESBLs). Th is was followed by Klebsiella spp., documented for blood culture collection, Gram stain, BC-GN result, conventional identifi cation and susceptibilities, and the fi rst dose of appropriate antibiotic. For this study, we chose a subset of GN organisms-Citrobacter spp., Enterobacter spp., Klebsiella spp. and Escherichia coli-as the recommended change in antibiotics was most diff erent from empiric therapy and was predicted to have a maximum impact upon change in antibiotics in response to stewardship recommendations. Other GN bacteria such as Pseudomonas aeruginosa, Proteus spp., and Acinetobacter spp. were also detected in the assay but were not considered because of the likelihood of minimal impact on empirical antibiotic usage. Appropriate adjustment was defi ned as deescalation of empiric therapy (vancomycin and piperacillin/ tazobactam) to the appropriate targeted coverage such as thirdor fourth-generation cephalosporins within 24 hours in response to the stewardship recommendations on the Verigene report (Table 1 ). Antibiotics were documented based on the date and time that the dose was given as recorded in the EHR. Patients who died during their hospital admission or were discharged before Verigene results were available were excluded.
Blood was collected at individual sites and transported via courier to med fusion. Upon arrival at med fusion, bottles were incubated on the BacT/ALERT automated blood culture system for up to 5 days. When the aerobic or anaerobic bottle was identifi ed as positive for bacterial growth, a Gram stain was performed, with inoculation on appropriate solid agar media. Plates were read after approximately 24 hours of incubation. Identifi cation and susceptibility testing were performed using • Consider discontinuing empiric Gram-positive coverage if appropriate.
• Consider a fourth-generation cephalosporin if appropriate.
• Deescalate further when susceptibility results are available.
Klebsiella pneumoniae, Klebsiella oxytoca, Escherichia coli
• Consider discontinuing empiric Gram-positive coverage if appropriate.
• Consider a third-generation cephalosporin if appropriate.
ESBL producer (CTX-M)
• Recommend use of meropenem.
• Deescalate when susceptibility results are available.
Carbapenemase producer (KPC, OXA, VIM, IMP, NDM)
• Initiate contact precautions.
• Consider infectious disease consult.
CTX-M indicates class A extended-spectrum beta-lactamases (Cefotaxime); IMP, imipenem-resistant metallo-beta-lactamase; KPC, K. pneumoniae carbapenemases; NDM, New Delhi metallo-β-lactamase; OXA, OXA-type beta-lactamases/class D beta-lactamases/ oxacillinases; VIM, Verona integron-encoded metallo-beta-lactamase. targeted antibiotics was made at 12.2 ± 13.5 hours in response to BC-GN results, which was signifi cantly earlier (P < 0.001) than when results by conventional methods became available (73.6 ± 40.0 hours). After accounting for patients already on recommended targeted therapy, polymicrobial infections, and patients deceased or lost to follow-up, we found antibiotic stewardship opportunities in ∼28% of GN infections. Further subanalysis demonstrated site-specifi c diff erences in the uptake of stewardship recommendations, whereby 32.4% of cases at Baylor University Medical Center, 50.5% at Baylor All Saints, and 15.0% at Baylor Irving demonstrated the expected change in antibiotics (Table 4) . We also noticed overuse of carbapenem/quinolone drug categories (only 9.6% of patients on carbapenem/quinolone were ESBL producers) at the Baylor Irving site.
DISCUSSION
Rapid identifi cation of GN bacteremia and key susceptibility markers can lead to many benefi ts, such as earlier deescalation of empiric therapy and switch to appropriate targeted antimicrobials that can lead to better patient outcomes, decreased length of hospital stay, and decreased overall hospital costs (9) (10) (11) (12) . Th e Verigene BC-GN assay has two major advantages favoring its routine use: a random-access format with very limited handson time and the ability to rapidly provide clinically actionable therapeutic information to physicians.
Our study demonstrated that implementation of the BC-GN panel across a multisite facility led to earlier deescalation of empiric therapy and switch to appropriate targeted antibiotics in approximately 29% of the cases. Multiple patients were shown to be on targeted antibiotic therapy from initial dosing (i.e., before organism identifi cation was available by Verigene BC-GN). Th e initial postulation was that the choice of antibiotics may be driven by order sets in the EHR, for which physicians may be directed to empiric therapy other than vancomycin and which constituted 20.5% of the isolates, with 10.3% of the Klebsiella spp. harboring ESBLs. Th e timeline of antibiotic adjustment in response to stewardship recommendations on the rapid BC-GN report is shown in Figure 1 . Across all three sites combined, 29.1% (262/899) of patients were transitioned from empiric to targeted therapy and made the expected change to antibiotics in response to stewardship recommendations within 24 hours. In the subset where an intervention was made, the switch to appropriate piperacillin/tazobactam, as it is not needed in all cases. However, further subset analysis by order sets demonstrated that there was no association between use of order sets to prescribe antibiotic therapy and changes in therapy in response to BC-GN result. Th ere was also no association of patient location (i.e., within or outside of the intensive care unit) and response to the BC-GN results (data not shown).
We determined that there were site-specifi c diff erences in antibiotic stewardship practices. Of interest, we identifi ed high empiric use of carbapenem/quinolone drug classes despite low identifi cation of ESBL on the BC-GN result at the Baylor Irving site. Although carbapenems are active in this setting, these high-cost agents should be reserved for the additional coverage of drug-resistant organisms (13, 14) . Th e outcome of this study will allow concentration of antimicrobial stewardship eff orts at this site. Confi dence in the rapid results on non-ESBL producers on the BC-GN panel combined with education should minimize the use of carbapenem/quinolone drug categories when not indicated. Further opportunities for discontinuation of empiric coverage and earlier switch to targeted therapy were identifi ed for approximately one-fourth of the cases.
Our study is comparable to previously published outcome studies on BC-GN rapid testing. Hill et al (10) evaluated the performance of the Verigene BC-GN assay and potential impact of rapid antibiotic interventions in 54 patients. BC-GN identifi ed the organism approximately 24 hours faster than conventional methods. Upon retrospective evaluation of medical records by the stewardship team, it was concluded that antibiotic management could have been modifi ed for 31.8% of patients an average of 33 hours sooner. Walker et al (12) did a retrospective review of GN bacteremia cases before (n = 98) and after (n = 97) Verigene BC-GN implementation and demonstrated that rapid implementation of eff ective therapy was statistically signifi cant for postintervention cases of ESBL-producing organisms (P = 0.049) but not overall (P = 0.12).
Th e study was limited, as it did not evaluate the economic savings to the hospital in terms of antibiotic usage, length of hospitalization, and mortality. Another limitation is that underlying diagnosis and associated complications were not evaluated. Larger prospective studies are warranted to support the fi ndings of our study and to address other important aspects infl uencing the routine use of this assay. 
